Allonix Therapeutics

Allonix Therapeutics is a pre-clinical stage biotechnology company focused on the discovery of next-generation small molecule drugs that utilize allosteric modulation and molecular glue mechanisms. The company was co-founded by leading scientists from the University of California, San Francisco (UCSF) and is backed by premier venture capital firms including OrbiMed and ARCH Venture Partners. Allonix's proprietary platform targets "undruggable" proteins, primarily in the field of oncology, to overcome resistance to existing therapies. By focusing on allosteric sites, the company aims to achieve superior selectivity and potency compared to traditional active-site inhibitors. Allonix is currently building a robust pipeline of internal programs aimed at high-impact cancer targets.